On April 23, 2026 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the first quarter ended March 28, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Quarter Highlights

•First quarter revenue grew 6% to $11.01 billion.
•First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43.
•First quarter adjusted EPS grew 6% to $5.44.

•Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company.

•Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included the Thermo Scientific Glacios 3 Cryo-TEM, a next-generation cryo-transmission electron microscope designed to enable installation in a broader range of lab spaces, democratizing access to cryo-EM for use in structural biology; the Thermo Scientific TSQ Certis triple quadrupole mass spectrometer, which enhances productivity and reliability by delivering faster, high-quality results to support analytical testing across pharmaceutical and applied laboratories; the Thermo Scientific Niton XL5e Handheld XRF Analyzer, which enables industrial and applied customers to improve the speed and accuracy of identifying materials in the field; and the Gibco CTS Compleo Fill and Finish System, which increases productivity and reliability in cell therapy manufacturing, supporting scalable production of advanced therapies.

•Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we announced a strategic collaboration with NVIDIA, combining our leadership in laboratory technologies with NVIDIA’s AI capabilities to advance scientific instrumentation, improve laboratory performance and accelerate scientific breakthroughs. We also announced a strategic collaboration with SHL Medical to deliver fully integrated sterile fill-finish and device assembly solutions, advancing our U.S. drug product manufacturing capabilities and helping pharma and biotech customers accelerate development and commercialization of important medicines.

•Continued to successfully execute our capital deployment strategy. During the quarter, we completed the acquisition of Clario, an industry-leading provider of endpoint data solutions, repurchased $3.0 billion of stock and increased our dividend by 10%.

"We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers’ success," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. "We continued to make great progress executing our strategy, further strengthening our capabilities with the addition of Clario."

Casper added, "Looking ahead, we are well positioned to deliver a strong year. As the trusted partner to our customers, we are uniquely equipped to help them accelerate their innovation and enhance their productivity. Through our global scale and the power of the PPI Business System, we will continue to actively manage the company to create value for our stakeholders and build an even brighter future for our company."

First Quarter 2026

Revenue for the first quarter of 2026 grew 6% to $11.01 billion, versus $10.36 billion in the same quarter of 2025. Organic revenue growth was 1%.

GAAP Earnings Results

GAAP diluted EPS in the first quarter of 2026 was $4.43, 11% growth versus the first quarter of 2025. GAAP operating income for the first quarter of 2026 was $1.86 billion, 9% higher than the year-ago quarter. GAAP operating margin was 16.9%, compared with 16.6% in the first quarter of 2025.

Non-GAAP Earnings Results

Adjusted EPS for the first quarter of 2026 was $5.44, 6% growth versus the first quarter of 2025. Adjusted operating income for the first quarter of 2026 was $2.40 billion, 6% higher than the year-ago quarter. Adjusted operating margin was 21.8%, compared with 21.9% in the first quarter of 2025.

Annual Guidance for 2026

The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

(Press release, Thermo Fisher Scientific, APR 23, 2026, View Source [SID1234664727])